<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rogerio C Lilenbaum, MD, FACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven E Schild, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Treatment of patients with lung cancer depends upon the cell type (non-small cell lung cancer [NSCLC] versus small cell lung cancer), molecular characteristics, tumor stage, and an assessment of the patient's overall medical condition.</p><p>Patients with stage I, II, or III NSCLC are generally treated with curative intent using surgery or radiation therapy (RT), sometimes combined with concurrent or adjuvant systemic therapy  (<a class="graphic graphic_table graphicRef109805" href="/z/d/graphic/109805.html" rel="external">table 1</a>). By contrast, palliative systemic therapy is appropriate for patients who have stage IV disease at presentation. Palliative systemic therapy is also used for patients who have relapsed with advanced disease following prior definitive treatment.</p><p>An improved understanding of the molecular pathways that drive malignancy in NSCLC has led to the development of agents that target specific molecular pathways in malignant cells. Therapy can then be individualized based upon the specific abnormality, if any, present in a given patient.</p><p>The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of patients with advanced NSCLC that contains a somatic mutation in <em>EGFR</em> will be reviewed here.</p><p>Other relevant topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4607.html" rel="external">"Overview of the initial treatment of advanced non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/114697.html" rel="external">"Brain metastases in non-small cell lung cancer", section on 'EGFR mutations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">RATIONALE</span></p><p class="headingAnchor" id="H177153446"><span class="h2">Molecular pathogenesis</span><span class="headingEndMark"> — </span>Tumor growth and progression depend upon the activity of cell surface membrane receptors that control intracellular signal transduction pathways regulating cell proliferation, apoptosis, angiogenesis, adhesion, and motility.</p><p>These cell surface receptors include the EGFR (also called HER1 or erbB-1) tyrosine kinases (TKs). EGFR exists as a monomer on the cell surface, and it must dimerize to activate the TK. While the TK activity of EGFR is tightly controlled in normal cells, the genes encoding these receptors may have escaped from their usual intracellular inhibitory mechanisms in malignant cells  (<a class="graphic graphic_figure graphicRef86507" href="/z/d/graphic/86507.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H177151213"><span class="h2">EGFR mutation as a predictor of responsiveness</span><span class="headingEndMark"> — </span>Advanced NSCLCs that contain characteristic mutations in <em>EGFR</em>, exon 19 deletions or exon 21 L858R mutations, are highly sensitive to EGFR TK inhibitors (TKIs). Analysis for the presence or absence of a driver mutation in <em>EGFR</em> is the standard approach to decide whether or not to use an EGFR TKI for the initial treatment of a patient with advanced NSCLC. Multiple reliable techniques are available to assay for <em>EGFR</em> mutations, and these are feasible on formalin fixed tissue [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a>.)</p><p>Mutations in the <em>EGFR</em> tyrosine kinase are observed in approximately 15 percent of NSCLC adenocarcinoma in the United States and occur more frequently in women and nonsmokers. In Asian populations, the incidence of <em>EGFR</em> mutations is substantially higher.</p><p>In the PIONEER study, tumor was analyzed from 1482 patients with adenocarcinoma in seven Asian regions (China, Hong Kong, India, Philippines, Taiwan, Thailand, Vietnam) [<a href="#rid2">2</a>]. The incidence of <em>EGFR</em> mutations ranged from 22 to 62 percent. Although <em>EGFR</em> mutations were more common in nonsmokers, the incidence still was 37 percent in regular smokers. The frequency of such mutations was higher in women than in men, but the difference was not significant after considering the frequency of smoking.</p><p>If systemic treatment is required before the results of genotype testing are available, systemic chemotherapy is indicated [<a href="#rid3">3</a>]. If an <em>EGFR</em> mutation is identified after initiation of chemotherapy, we suggest continuing chemotherapy for four cycles as long as therapy is tolerated and there is no evidence of disease progression. When the results of genotype testing become available, the treatment plan should be reassessed. There are no clinical trials that directly address the optimal approach when a driver mutation is identified after chemotherapy has been initiated.</p><p class="headingAnchor" id="H539252951"><span class="h3">Avoidance of EGFR overexpression as a predictor of responsiveness</span><span class="headingEndMark"> — </span>Unlike activating mutations in <em>EGFR</em>, amplification of <em>EGFR</em> does not predict improved outcomes with EGFR inhibitors. Furthermore, EGFR overexpression by immunohistochemistry is not sufficiently predictive of activity of EGFR TKIs to be an appropriate surrogate for the presence of an activating <em>EGFR</em> mutation.</p><p>In the IPASS trial, high <em>EGFR</em> gene copy number was associated with improved progression-free survival (PFS) with <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> over chemotherapy only if there was a coexisting <em>EGFR</em> mutation (hazard ratio [HR] 0.48; 95% CI, 0.34-0.67) [<a href="#rid4">4</a>]. However, if high <em>EGFR</em> gene copy number was not accompanied with an <em>EGFR</em> mutation, PFS outcomes were worse with gefitinib compared with chemotherapy (HR 3.85, 95% CI 2.09-7.09).</p><p class="headingAnchor" id="H619542310"><span class="h2">Clinical predictors of responsiveness</span><span class="headingEndMark"> — </span>Initial studies identified several clinical parameters that were associated with a high response rate to EGFR TKIs and a relatively favorable prognosis. These include adenocarcinoma histology, women, nonsmokers, and Asian ethnicity. Subsequent studies showed that these clinical parameters are surrogates for the presence of specific activating mutations in the tyrosine kinase domain of the <em>EGFR</em> (exon 19 deletions, L858R point mutation in exon 21). However, clinical parameters should not replace actual mutational testing since clinical profiling is not highly accurate [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H4"><span class="h1">EFFICACY OF SINGLE-AGENT EGFR TKIS</span></p><p class="headingAnchor" id="H888692933"><span class="h2">Preferred: Osimertinib, with or without chemotherapy</span><span class="headingEndMark"> — </span>We suggest <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a>, with or without chemotherapy, as the initial strategy for advanced NSCLC with <em>EGFR</em> exon 19 deletions or exon 21 L858R mutations. (See <a class="local">'Alternatives'</a> below and <a class="local">'Immune-related toxicities with EGFR TKI after immunotherapy'</a> below.)</p><p><a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">Osimertinib</a> is approved by the US Food and Drug Administration (FDA) for the first-line treatment of patients with metastatic NSCLC whose tumors have <em>EGFR</em> exon 19 deletions or exon 21 L858R mutations [<a href="#rid5">5</a>], and has shown benefit over older EGFR tyrosine kinase inhibitors. Osimertinib has been associated with QTc prolongation as well as decreases in left ventricular ejection fraction, which are reversible with discontinuation of the drug [<a href="#rid6">6</a>]. Subsequent data have shown progression-free survival (PFS) benefits with the addition of chemotherapy to osimertinib at the expense of added toxicity, but survival benefits are unknown. Although we have not incorporated this strategy into our clinical practice pending longer term data, we recognize that it is an acceptable strategy.</p><p>Data regarding these strategies are below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single-agent </strong><strong>osimertinib</strong> – In the phase III FLAURA trial, 556 patients with treatment-naïve, <em>EGFR-</em>mutated advanced NSCLC were randomly assigned to <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> versus standard of care (SOC) EGFR TKI (<a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> or <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>) [<a href="#rid7">7</a>]. Neurologically stable patients with central nervous system metastases were permitted in this study. Osimertinib demonstrated improvement in PFS (18.9 versus 10.2 months; hazard ratio [HR] 0.46, 95% CI 0.37-0.57) and duration of response (17.2 versus 8.5 months) relative to SOC. The PFS benefit was consistent across subgroups, including either patients with or without brain metastases. In reporting of overall survival (OS) results at 58 percent maturity, osimertinib improved OS relative to SOC (38.6 versus 31.8 months; HR 0.80, 95% CI 0.64-0.997) [<a href="#rid8">8</a>]. Response rates for osimertinib and SOC were 80 and 76 percent, respectively. Grade 3 or higher toxicities were lower for osimertinib versus SOC (34 versus 45 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osimertinib</strong><strong> with chemotherapy</strong> – In a randomized open-label trial including 557 patients with advanced <em>EGFR</em>-mutated NSCLC, the addition of platinum-pemetrexed chemotherapy to <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> improved PFS, as assessed by blinded, independent central review (29.4 versus 19.9 months; HR 0.62, 95% CI 0.48-0.80) [<a href="#rid9">9</a>]. Patients assigned to osimertinib plus chemotherapy received four cycles of investigator's choice of platinum agent plus <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">pemetrexed</a>, with pemetrexed continuing as maintenance therapy, along with osimertinib. Although OS results are immature, at 24 months the OS rate with osimertinib-chemotherapy was 79 versus 73 percent with osimertinib alone (HR 0.90, 95% CI 0.65-1.24). Adverse events of grade 3 or higher were reported in 64 percent in the osimertinib-chemotherapy group and in 27 percent in the osimertinib group.</p><p></p><p>Potential approaches to patients with resistance to <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> are discussed below. (See <a class="local">'Resistance to osimertinib-based therapy'</a> below.)</p><p class="headingAnchor" id="H2383968982"><span class="h2">Alternatives</span><span class="headingEndMark"> — </span>Data comparing <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a>, <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>, and <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a> with chemotherapy and each other are discussed in the sections below. However, data suggest improved outcomes with <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a>, which is discussed above. (See <a class="local">'Preferred: Osimertinib, with or without chemotherapy'</a> above.)</p><p class="headingAnchor" id="H1506273"><span class="h3">Erlotinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">Erlotinib</a> has been compared with chemotherapy in several randomized trials in patients with <em>EGFR</em>-mutated lung cancer, summarized below, all of which demonstrated a benefit in progression free survival with erlotinib, but not in OS. This likely reflects the effect that post-trial treatments have on OS, especially given that cross-over to TKI upon progression on chemotherapy was permitted.</p><p>Trials of <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> versus chemotherapy are discussed here. One study assessed erlotinib versus <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> and is discussed below. (See <a class="local">'Gefitinib'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>OPTIMAL trial</strong> – 154 patients were randomly assigned to <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> or <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> [<a href="#rid10">10</a>]. Treatment with erlotinib improved PFS compared with chemotherapy (13.1 versus 4.6 months, HR 0.16, 95% CI 0.10-0.26). Similarly, the objective response rate was improved with erlotinib (83 versus 36 percent). OS in patients receiving erlotinib versus chemotherapy was not significantly different (22.8 versus 27.2 months, HR 1.19, 95% CI 0.83-1.71) [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>EURTAC trial</strong> – 174 patients were randomly assigned to <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> or a platinum-based chemotherapy doublet [<a href="#rid12">12</a>]. PFS was increased with erlotinib compared with chemotherapy (9.7 versus 5.2 months, HR 0.37, 95% CI 0.25-0.54). There was no difference in OS in the erlotinib versus chemotherapy groups (19.3 versus 19.5 months, HR 1.04, 95% CI 0.65-1.68).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ENSURE trial</strong> – Two-hundred seventy-five patients were randomized to <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> or <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid13">13</a>]. Patients treated with erlotinib experienced an improved PFS compared with chemotherapy (11.0 versus 5.5 months, HR 0.34, 95% CI 0.22-0.51). Median OS was similar in the two groups (26.3 versus 25.5 months, HR 0.91, 95% CI 0.63-1.31).</p><p></p><p>For patients receiving <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>, we avoid concomitant use of proton pump inhibitors, given observational evidence of decreased efficacy of erlotinib [<a href="#rid14">14</a>]. Further details regarding drug interactions are found in the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p class="headingAnchor" id="H1787393343"><span class="h3">Gefitinib</span><span class="headingEndMark"> — </span>While <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> previously was approved outside the United States for patients with <em>EGFR</em> driver mutations, it was subsequently approved by the FDA for patients whose tumor contains an <em>EGFR</em> exon 19 deletion or the exon 21 (L858R) substitution mutation [<a href="#rid15">15</a>]. It is an appropriate option in this setting.</p><p><a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">Gefitinib</a> was compared with cytotoxic chemotherapy as the initial therapy in three randomized trials in patients with advanced NSCLC whose tumors contained activating <em>EGFR</em> mutations. The most extensive data come from the IPASS trial, in which 1217 patients were randomly assigned to gefitinib or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> [<a href="#rid4">4,16</a>]. Patients were included based upon clinical criteria consistent with responsiveness to gefitinib; all were Asian, had adenocarcinoma and were either never smokers or former light smokers. For the entire cohort, PFS was significantly better with gefitinib compared with chemotherapy (12-month progression-free rate 25 versus 7 percent, HR for progression 0.74). The difference in OS was not statistically significant (median 18.8 versus 17.4 months, HR for death 0.90, 95% CI 0.79-1.02) [<a href="#rid4">4</a>].</p><p>Results depended upon the <em>EGFR</em> mutation status. <em>EGFR</em> mutations were present in 60 percent of the 437 evaluable patients; among these, 96 percent had either an exon 19 deletion or the exon 21 L858R mutation.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients whose tumors contained an <em>EGFR</em> mutation, PFS was significantly prolonged with <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> compared with <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> (median 9.5 versus 6.3 months, HR for progression 0.48) [<a href="#rid16">16</a>]. OS was not increased (median 22 months in both groups, HR 1.00) [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those without an <em>EGFR</em> mutation, PFS was significantly shorter with <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> (median 1.5 versus 6.5 months, HR 2.85 for progression, 95% CI 2.05-3.95) [<a href="#rid16">16</a>]. The difference in OS was not statistically significant (median 11.2 versus 12.7 months, HR for death 1.18).</p><p></p><p>Two additional phase III trials were conducted exclusively in patients with <em>EGFR</em> mutations (the West Japan Oncology Group 172 trial [<a href="#rid17">17,18</a>] and the North-East Japan Study Group 002 trial [<a href="#rid19">19,20</a>]). The overall results and magnitude of the benefit were essentially the same as in the IPASS trial.</p><p class="headingAnchor" id="H7874695"><span class="h3">Afatinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">Afatinib</a> is as an irreversible EGFR TKI, which has been shown to have clinical activity in multiple clinical trials [<a href="#rid21">21-25</a>].</p><p><a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">Afatinib</a> was compared with chemotherapy as the initial therapy for advanced NSCLC in two phase III trials in patients whose tumors contain activating mutations. The efficacy of afatinib in this setting is illustrated by the results of the phase III Lux-Lung 3 trial, in which 345 previously untreated patients were randomly assigned to treatment with afatinib or <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">pemetrexed</a> [<a href="#rid23">23,24</a>]. The primary endpoint of the trial was PFS based upon independent review.</p><p>At a median follow-up of 16 months, key results included the following:</p><p class="bulletIndent1"><span class="glyph">●</span>PFS was significantly increased with <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a> compared with chemotherapy (median 11.1 months versus 6.9 months, 12-month progression-free rate 51 versus 21 percent, HR for progression 0.58, 95% CI 0.43-0.78).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The objective response rate was significantly increased with <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a> (56 versus 23 percent). Time to symptom progression and quality of life were also significantly improved with afatinib.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most frequent side effects included diarrhea, rash, stomatitis, paronychia, and dry skin (95, 89, 72, 57, and 29 percent of cases, respectively), and were consistent with those seen with other EGFR TKIs. (See <a class="local">'EGFR TKI toxicity'</a> below.)</p><p></p><p>A second phase III trial was conducted in 364 Asian patients (Lux-Lung 6), in which <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a> was compared with <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid26">26</a>]. Similar results were observed with afatinib resulting in an increased PFS (11.0 versus 5.6 months) and improved response rate (67 versus 23 percent).</p><p>In a combined analysis of these two trials (n = 709), the median OS was not significantly increased for patients assigned to <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a> compared with chemotherapy (median 25.8 versus 24.5 months, HR for death 0.91, 95% CI 0.75-1.11) [<a href="#rid27">27</a>]. When the combined trial data were analyzed based upon the specific mutation present, a statistically significant benefit was observed in OS and PFS in patients with exon 19 deletion. There was a significant benefit in progression-free, but not OS for those with the L858R mutation.</p><p><a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">Afatinib</a> in NSCLC with uncommon <em>EGFR</em> mutations is discussed below. (See <a class="local">'EGFR S768I, L861Q, and G719X mutations'</a> below.)</p><p class="headingAnchor" id="H1327252584"><span class="h3">Comparisons of gefitinib, erlotinib, and afatinib</span><span class="headingEndMark"> — </span>Available data suggest that <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>, <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a>, and <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a> all have efficacy in <em>EGFR</em>-mutant lung cancer and are generally well tolerated. Some data suggest that afatinib may yield the strongest disease outcomes but may also cause the most side effects [<a href="#rid28">28,29</a>]. Some evidence suggests gefitinib may be the best tolerated of the agents, though this has not been consistently observed. <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">Osimertinib</a> is preferred in the front-line setting, however. (See <a class="local">'Preferred: Osimertinib, with or without chemotherapy'</a> above.)</p><p class="headingAnchor" id="H177153170"><span class="h2">Brain metastases</span><span class="headingEndMark"> — </span>Surgery and/or radiation therapy may be indicated for patients with brain metastases from NSCLC. In selected patients with brain metastases whose tumor possesses an activating mutation of the <em>EGFR</em> tyrosine kinase, treatment with an EGFR TKI may possess clinically useful activity against the brain lesion. Efficacy of <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> against brain metastases is discussed above. (See  <a class="medical medical_review" href="/z/d/html/5217.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of brain metastases"</a> and  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases"</a> and  <a class="medical medical_review" href="/z/d/html/114697.html" rel="external">"Brain metastases in non-small cell lung cancer", section on 'EGFR mutations'</a> and <a class="local">'Preferred: Osimertinib, with or without chemotherapy'</a> above.)</p><p class="headingAnchor" id="H1191492196"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>Treatment with an EGFR TKI is generally continued until there is disease progression. However, some patients have rapid disease progression when therapy with an EGFR TKI is discontinued after a prolonged course of treatment. This has led some groups to continue the EGFR TKI in patients with progressive disease who had an initial response to treatment [<a href="#rid30">30-32</a>]. However, when chemotherapy is initiated, treatment with EGFR TKI generally should be discontinued.</p><p>The IMPRESS trial in 265 NSCLC patients whose tumor contained an activating mutation in <em>EGFR</em> compared chemotherapy plus <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> versus chemotherapy alone after disease progression on first-line gefitinib [<a href="#rid33">33,34</a>]. This trial found that continuing gefitinib in conjunction with chemotherapy did not prolong PFS compared with chemotherapy alone and was associated with a shorter OS compared with placebo.</p><p class="headingAnchor" id="H703880782"><span class="h1">RESISTANCE TO EGFR TKIS</span></p><p class="headingAnchor" id="H1127440876"><span class="h2">Approach</span><span class="headingEndMark"> — </span>The use of EGFR tyrosine kinase inhibitors (TKIs) should be integrated with other treatment strategies to prolong survival and maintain quality of life for as long as possible. For patients with an <em>EGFR</em> mutation who progress on an EGFR TKI and are found to have a substitution of methionine for threonine at position 790 (<em>T790M</em>) mutation, we treat with <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a>. (See <a class="local">'Osimertinib'</a> below.)</p><p>Methods of assessing for <em>T790M</em> are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'Molecular testing'</a>.)</p><p>For patients who do not have a <em>T790M</em> mutation, or for those who progress on <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a>, combination chemotherapy, with or without the addition of immunotherapy, is usually the next treatment option when progressive disease develops. (See <a class="local">'Resistance to osimertinib-based therapy'</a> below.)</p><p>Chemotherapy with platinum-etoposide is recommended for patients with evidence of small cell transformation, after standard EGFR TKI therapy [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H3174368943"><span class="h2">Mechanisms</span><span class="headingEndMark"> — </span>Almost all patients who initially respond to an EGFR TKI subsequently develop disease progression. The causes of acquired resistance are not fully understood, but include secondary mutations in <em>EGFR</em> (eg,<em> T790M</em>)<em> </em>[<a href="#rid36">36-39</a>], amplification of <em>MET </em>[<a href="#rid40">40-45</a>], and histologic transformation to small cell lung cancers [<a href="#rid46">46,47</a>].</p><p>Tumors with neuroendocrine transformation may be sensitive to small cell lung cancer chemotherapy regimens [<a href="#rid46">46,48</a>]. (See  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management", section on 'Initial treatment'</a>.)</p><p class="headingAnchor" id="H158587821"><span class="h2">Resistance to gefitinib, erlotinib, or afatinib</span></p><p class="headingAnchor" id="H33857528"><span class="h3">Osimertinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">Osimertinib</a> was granted accelerated approval by the US Food and Drug Administration (FDA) for use in patients with NSCLC harboring a <em>T790M</em> mutation whose disease progressed on other <em>EGFR</em>-inhibiting therapy, based on results of a phase I/II study suggesting a response rate of 61 percent and median progression-free survival (PFS) of 10 months in this setting [<a href="#rid49">49</a>]. In the subsequent phase III trial of 419 patients with <em>T790M</em>-positive NSCLC who had progressed on first-line EGFR TKI, osimertinib demonstrated improved PFS (10.1 versus 4.4 months; hazard ratio [HR] for progression or death 0.30, 95% CI 0.23-0.41) and objective response rate (71 versus 31 percent; odds ratio [OR] for objective response 5.4, 95% CI 3.47-9.48) compared with a pemetrexed- and platinum-based chemotherapy combination [<a href="#rid50">50</a>]. At longer follow-up of over 20 months, the median overall survival (OS) was 27 versus 23 months for osimertinib versus platinum-pemetrexed, respectively (HR 0.87, 95% CI 0.67-1.12) [<a href="#rid51">51</a>]. Although the difference was not statistically significant, crossover may have affected these results. Grade 3 or higher toxicities were lower with osimertinib than chemotherapy (23 versus 47 percent).</p><p>Among the 144 patients with central nervous system (CNS) disease, the median duration of PFS was longer with <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> than with chemotherapy (8.5 versus 4.2 months; HR 0.32, 95% CI 0.21-0.49). Preliminary results demonstrated higher CNS response rates with osimertinib among those with measurable disease (40 versus 17 percent; OR 3.24, 95% CI 1.33-8.81) and longer CNS PFS among those with either measurable or nonmeasurable disease (11.7 versus 5.6 months; HR 0.32, 95% CI 0.15-0.69) [<a href="#rid52">52</a>].</p><p>Additional randomized clinical trials are ongoing to determine the role of other agents in patients with an activating mutation. For example, agents such as rociletinib and HM61713 also demonstrate activity against <em>EGFR</em>-mutant tumors with the <em>T790M</em> resistance mutation, though these are not approved by the FDA [<a href="#rid53">53-55</a>].</p><p>The irreversible EGFR TKI <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a> may also have some activity in patients with acquired resistance to <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> or <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> [<a href="#rid21">21</a>]. Results of a phase III trial in patients who had progressed after both chemotherapy and an EGFR TKI (either erlotinib or gefitinib) found that afatinib increased PFS but did not improve OS [<a href="#rid21">21</a>]. (See <a class="local">'Afatinib'</a> above.)</p><p class="headingAnchor" id="H3788752822"><span class="h2">Resistance to osimertinib-based therapy</span><span class="headingEndMark"> — </span>There are no targeted agents that are FDA approved for those who have progressed on <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> (either in the adjuvant or metastatic setting).</p><p>Consistent with expert guidelines, we typically biopsy a site of progressive disease to determine if another targetable mutation is present [<a href="#rid35">35</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>If an actionable driver mutation is identified, we treat with the appropriate targeted agent. (See  <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If no alternative actionable driver mutation is identified, our approach to those with progression on <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> is to offer treatment with a platinum-based chemotherapy regimen, similar to those without an <em>EGFR</em> mutation who are chemotherapy naϊve.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with small cell transformation, a platinum-etoposide regimen is typically used [<a href="#rid35">35</a>], with or without an immune checkpoint inhibitor.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those without small cell transformation, the combination of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> plus platinum-based chemotherapy could be considered an alternative option [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The addition of the anti-programmed cell death-ligand 1 (PD-L1) antibody <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> to <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and platinum-based doublet chemotherapy has been shown to improve PFS, with a trend toward improved OS, in nonsquamous NSCLC, including among those with activating driver mutations. However, in this subset, trial results are conflicting.</p><p></p><p class="bulletIndent2">In the IMpower 150 trial, the addition of <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> to the combination of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, and <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> improved PFS among 800 patients with advanced NSCLC [<a href="#rid56">56</a>]. The benefit was also seen in the subset of 111 patients with <em>EGFR</em> mutations or anaplastic lymphoma kinase (<em>ALK</em>) translocations, all of whom had progressed on a prior targeted agent (median PFS, 9.7 versus 6.1 months; HR 0.59, 95% CI 0.37-0.94; median OS, not estimable versus 17. 5 months; HR 0.54, 95% CI 0.29-1.03) [<a href="#rid57">57</a>]. In the overall study population, serious adverse events occurred in 25 percent of those who also received atezolizumab versus 19 percent of those receiving standard therapy only. Further details of this study are described elsewhere. (See  <a class="medical medical_review" href="/z/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation", section on 'In nonsquamous cancers'</a>.)</p><p></p><p class="bulletIndent2">In contrast to IMpower 150, the addition of <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> to initial chemotherapy (<a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">nabpaclitaxel</a> and <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>) did not improve PFS (HR 0.75, 95% CI 0.36-1.54) or OS (HR 0.98, 95% CI 0.41-2.31) in the subset of 44 patients with <em>EGFR</em>-<em> </em>or<em> ALK</em>-positive NSCLC in IMpower 130 [<a href="#rid58">58</a>]. We await full reporting and follow-up of these trials for clarification on the role of immunotherapy for those with activating driver mutations, upon progression on available targeted agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with no other actionable driver mutation who have progressed on both platinum-based chemotherapy and <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> (either sequentially or in combination), options include enrollment in a clinical trial, palliative care only, or single-agent chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/4629.html" rel="external">"Subsequent line therapy in non-small cell lung cancer lacking a driver mutation"</a>.)</p><p></p><p>Studies are evaluating mechanisms of resistance to <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a>. For example, in one study of patients with advanced NSCLC who received osimertinib for <em>T790M</em>-positive acquired resistance to an early-generation EGFR TKI, loss of <em>T790M</em> at the time of progression on osimertinib was identified as a resistance mechanism [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H594516523"><span class="h1">UNCOMMON EGFR MUTATIONS</span></p><p class="headingAnchor" id="H3077534652"><span class="h2">EGFR exon 20 insertion mutations</span></p><p class="headingAnchor" id="H2076397499"><span class="h3">For treatment-naïve disease</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="131693" href="/z/d/drug information/131693.html" rel="external">Amivantamab</a> is a bispecific EGFR and MET receptor antibody that has shown progression-free survival (PFS) improvements when combined with front-line chemotherapy for patients with <em>EGFR</em> exon 20 insertion mutations. We suggest its use with chemotherapy in this setting, if available, while recognizing that it does not yet have regulatory approval for this indication, and availability may therefore be restricted. If amivantamab is unavailable for front-line use, we treat patients with <em>EGFR</em> exon 20 insertion mutations with platinum-based chemotherapy alone, reserving targeted therapy for next line treatment. (See <a class="local">'For those treated with initial chemotherapy'</a> below.)</p><p>In a randomized trial in 308 patients with advanced NSCLC with <em>EGFR</em> exon 20 insertions who had not received previous systemic therapy, those assigned to <a class="drug drug_general" data-topicid="131693" href="/z/d/drug information/131693.html" rel="external">amivantamab</a> plus chemotherapy experienced a longer PFS relative to those assigned to chemotherapy alone (11.4 versus 6.7 months; HR 0.40, 95% CI 0.30-0.53) [<a href="#rid60">60</a>]. At 18 months, PFS rates were also improved with the addition of amivantamab to chemotherapy, 31 percent versus 3 percent, respectively. At median follow-up of approximately 15 months, response rates were 73 versus 47 percent, respectively (rate ratio 1.50, 95% CI 1.32-1.68). In the interim overall survival analysis (with 33 percent maturity), the HR for death for amivantamab–chemotherapy versus chemotherapy alone was 0.67 (95% CI 0.42-1.09). Grade ≥3 adverse effects occurred in 75 percent in the amivantamab-chemotherapy group and 54 percent with chemotherapy alone. The most common adverse events in the amivantamab-chemotherapy group were reversible hematologic effects.</p><p class="headingAnchor" id="H1821691432"><span class="h3">For those treated with initial chemotherapy</span><span class="headingEndMark"> — </span>For patients with <em>EGFR</em> exon 20 insertion-mutated NSCLC that have progressed on chemotherapy (either with or without immunotherapy), we suggest <a class="drug drug_general" data-topicid="131693" href="/z/d/drug information/131693.html" rel="external">amivantamab</a> as a later-line option.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amivantamab</strong> – <a class="drug drug_general" data-topicid="131693" href="/z/d/drug information/131693.html" rel="external">Amivantamab</a> is approved by the US Food and Drug Administration (FDA) for patients with locally advanced or metastatic NSCLC with<em> EGFR </em>exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1">In a phase I study, among 81 patients with advanced NSCLC with <em>EGFR</em> exon 20 insertions that had experienced progression on platinum-based chemotherapy, the overall response rate with <a class="drug drug_general" data-topicid="131693" href="/z/d/drug information/131693.html" rel="external">amivantamab</a> was 40 percent, the clinical benefit rate (stable disease for at least 11 weeks or response to treatment) was 74 percent, and the median duration of response was 11.1 months [<a href="#rid62">62</a>]. Median progression-free survival was 8.3 months, and the median overall survival was 23 months.</p><p></p><p class="bulletIndent1">The most frequent adverse events (AEs) were rash (86 percent), infusion-related reaction (IRR; 66 percent), and paronychia (45 percent). Additional EGFR-related AEs were stomatitis (21 percent), pruritus (17 percent), and diarrhea (12 percent). Grade ≥3 AEs were reported in 35 percent of patients; 16 percent were related to treatment, with rash (4 percent) and IRR (3 percent) being the most common.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – <a class="drug drug_general" data-topicid="132715" href="/z/d/drug information/132715.html" rel="external">Mobocertinib</a> is an oral tyrosine kinase inhibitor that was previously approved by the FDA for patients with locally advanced or metastatic NSCLC with <em>EGFR</em> exon 20 insertion mutations progressive on or after platinum-based chemotherapy, but the manufacturer is removing it from the market because of lack of efficacy in the confirmatory trial. Other agents, including zipalertinib [<a href="#rid63">63</a>] are under investigation.</p><p></p><p class="headingAnchor" id="H3856671771"><span class="h2">EGFR S768I, L861Q, and G719X mutations</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">Afatinib</a> is also approved for the first-line treatment of patients with NSCLC whose tumors contain <em>EGFR</em> mutations S768I, L861Q, and G719X, as well as those that harbor the more common activating genetic alterations (exon 19 deletions or exon 21 L858R). However, afatinib is not the ideal treatment for all uncommon <em>EGFR</em> mutations [<a href="#rid64">64</a>]. In a pooled posthoc analysis of three trials in which afatinib was compared with platinum-based chemotherapy as initial treatment for those with <em>EGFR</em> mutations, clinical benefit was lower in patients with de novo Thr790Met and exon 20 insertion mutations compared with those with <em>EGFR</em> S768I, L861Q, or G719X mutations [<a href="#rid64">64,65</a>].</p><p><a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">Osimertinib</a> has also demonstrated favorable activity in patients with uncommon <em>EGFR</em> mutations. In an observational study of 37 patients with metastatic or recurrent NSCLC harboring <em>EGFR</em> mutations other than the exon 19 deletion, L858R and T790M mutations, or the exon 20 insertion, the objective response rate was 50 percent [<a href="#rid66">66</a>]. Approximately 60 percent of patients received osimertinib as first-line therapy. Although, for those with advanced NSCLC associated with uncommon <em>EGFR</em> mutations, we typically offer <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a>, given the FDA approval for this indication, osimertinib is a reasonable alternative.</p><p class="headingAnchor" id="H439704586"><span class="h1">COMBINATION REGIMENS</span><span class="headingEndMark"> — </span>EGFR tyrosine kinase inhibitors (TKIs) have been studied in combination both with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">ramucirumab</a>, antibodies targeting vascular endothelial growth factor (VEGF), and with chemotherapy.</p><p>Such combinations, however, are less favored options, compared with <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> in the front-line setting. (See <a class="local">'Preferred: Osimertinib, with or without chemotherapy'</a> above.)</p><p class="headingAnchor" id="H177152529"><span class="h1">EGFR TKI TOXICITY</span><span class="headingEndMark"> — </span>Important toxicities associated with inhibition of the EGFR pathway include a characteristic rash, diarrhea, and uncommonly interstitial pneumonitis.</p><p class="headingAnchor" id="H177152536"><span class="h2">Rash</span><span class="headingEndMark"> — </span>All agents targeting the EGFR pathway, including both small molecule tyrosine kinase inhibitors (TKIs) as well as monoclonal antibodies that bind <em>EGFR</em>, are associated with dermatologic toxicity (predominantly dry skin and an acneiform rash, although more severe reactions have been reported). This is thought to be due to high levels of <em>EGFR</em> expression in the basal layer of the epidermis. (See  <a class="medical medical_review" href="/z/d/html/15764.html" rel="external">"Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors"</a>.)</p><p class="headingAnchor" id="H177152543"><span class="h2">Gastrointestinal toxicity</span><span class="headingEndMark"> — </span>Diarrhea is common in patients receiving small-molecule EGFR TKIs. It has been reported in a majority of patients (especially with <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a>), but it is only occasionally severe and typically can be easily managed by the use of <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a>. Rarely, episodes of gastrointestinal perforation, some of which were fatal, have also been reported in patients receiving <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Small molecule EGFR inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'EGFR inhibitors'</a>.)</p><p class="headingAnchor" id="H177152550"><span class="h2">Pulmonary toxicity</span><span class="headingEndMark"> — </span>Potentially fatal lung toxicity has been reported with <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>, <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a>, and <a class="drug drug_general" data-topicid="119171" href="/z/d/drug information/119171.html" rel="external">dacomitinib</a>. (See  <a class="medical medical_review" href="/z/d/html/4336.html" rel="external">"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Anti-EGFR agents'</a>.)</p><p class="headingAnchor" id="H177152557"><span class="h2">Hepatic toxicity</span><span class="headingEndMark"> — </span>Hepatic failure and hepatorenal syndrome, potentially resulting in death, have been reported in patients treated with <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>. Patients with hepatic impairment should be closely monitored during treatment with erlotinib, and extra caution should be used in those with an elevated serum bilirubin. (See  <a class="medical medical_review" href="/z/d/html/128144.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents", section on 'Erlotinib and gefitinib'</a>.)</p><p class="headingAnchor" id="H3018028521"><span class="h2">Ocular toxicity</span><span class="headingEndMark"> — </span>All EGFR inhibitors have been associated with dysregulated hair cycles, which may lead to trichomegaly or trichiasis, with eyelashes directed at the cornea. Poor healing of the outermost epithelial layer of the cornea is reported with all EGFR inhibitors, leading to dry eyes, and persistent corneal epithelial defects and erosions as well as corneal thinning that may predispose to corneal perforation. <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">Erlotinib</a> can cause conjunctivitis, eyelid changes such as entropion and ectropion, and rarely, anterior uveitis. Clinical trials with <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> have reported mostly dry eye, blepharitis, conjunctivitis, and visual disturbances such as hemianopia, blurred vision, and photophobia. (See  <a class="medical medical_review" href="/z/d/html/96203.html" rel="external">"Ocular side effects of systemically administered chemotherapy", section on 'Epidermal growth factor receptor (EGFR) inhibitor'</a>.)</p><p class="headingAnchor" id="H2323776411"><span class="h2">Immune-related toxicities with EGFR TKI after immunotherapy</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> is our suggested front-line option for <em>EGFR</em>-mutated, advanced NSCLC, some patients may have already been exposed to immunotherapy, for example, as part of treatment for unresectable stage III disease (<a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a>), or because their <em>EGFR</em> status was unknown at the time of diagnosis. For such patients, we suggest delaying osimertinib for at least three months following completion of immunotherapy in order to avoid excess in toxicities associated with EGFR tyrosine kinase inhibitors (TKIs) following immunotherapy. Chemotherapy during this interval may be appropriate for some. Alternatively, for patients who require immediate treatment and are poor candidates for chemotherapy, proceeding directly with an EGFR inhibitor may be preferred, after a clear discussion of the potential risks and benefits. In such instances, we often opt for <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> rather than osimertinib, recognizing that although the increased toxicities with EGFR inhibition after immunotherapy may be a class effect, observational data suggest that the association may be stronger for osimertinib than for other EGFR inhibitors.</p><p>In an observational study including 41 patients treated first with programmed cell death ligand 1 (PD-L1) blockade and then with <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a>, 15 percent experienced a severe immune-related adverse event [<a href="#rid67">67</a>]. These toxicities were most common among those who initiated osimertinib within three months of prior immunotherapy (5 of 21 patients, 24 percent) versus those who initiated it within 3 to 12 months (1 of 8 patients, 13 percent) or after 12 months (0 of 12 patients, 0 percent). By contrast, no severe immune-related adverse events (AEs) were observed among the 29 patients who received osimertinib and then immunotherapy.</p><p>While in this study, the association appeared to be specific to <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> (with no severe immune-related AEs noted among the 27 patients treated first with immunotherapy and then with either <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a> or <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>), severe pneumonitis with erlotinib following <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> has been reported elsewhere [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H285002331"><span class="h1">CHEMOTHERAPY</span></p><p class="headingAnchor" id="H2192723099"><span class="h2">Those initially treated with chemotherapy in whom a mutation is subsequently identified</span><span class="headingEndMark"> — </span>Most patients with advanced NSCLC whose tumors contain a driver mutation are initially treated with the appropriate targeted agent (eg, <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>, <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a>, <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a>). For patients with advanced NSCLC who were initially treated with chemotherapy but in whom a driver mutation has subsequently been identified, continuation of therapy is indicated with an appropriate targeted agent after the initial cycles of chemotherapy are complete. However, if an immune checkpoint inhibitor was used as part of initial management, the risk of immune-mediated pneumonitis rises with subsequent use of <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> (and possibly other EGFR tyrosine kinase inhibitors [TKIs]). This risk and management are discussed elsewhere. (See <a class="local">'Immune-related toxicities with EGFR TKI after immunotherapy'</a> above.)</p><p>There are no randomized trials directly addressing the situation in which patients are found to have an <em>EGFR</em> mutation or other driver mutation after the initiation of chemotherapy. However, analysis of outcomes based upon mutation status in a subset of patients in the SATURN trial provides evidence that maintenance therapy with <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> after chemotherapy substantially improves progression-free survival (PFS) in these patients [<a href="#rid69">69,70</a>]. In the SATURN trial, previously untreated patients with advanced NSCLC were treated with four cycles of platinum-based doublet chemotherapy. Patients with an objective response or stable disease were then randomly assigned to treatment with erlotinib or placebo. <em>EGFR</em> mutation status was not determined prior to inclusion in the clinical trial.</p><p>Subsequently, tumor samples were analyzed for an <em>EGFR</em> mutation in 437 of the randomized patients [<a href="#rid69">69</a>]. <em>EGFR </em>mutations were detected in 49 cases (11 percent), while 388 were wildtype (89 percent). For patients with an <em>EGFR</em> mutation, PFS was significantly increased in those receiving maintenance <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> compared with placebo (median, 45 versus 13 weeks; hazard ratio for progression 0.10, 95% CI 0.04-0.25). Differences in overall survival were not statistically significant for patients with an <em>EGFR </em>mutation, but 67 percent of patients given a placebo subsequently received an EGFR TKI as second-line therapy.</p><p class="headingAnchor" id="H366264599"><span class="h2">Those with progression on an EGFR inhibitor</span><span class="headingEndMark"> — </span>For some patients who develop resistance to an EGFR inhibitor, chemotherapy may be indicated. The approach is discussed above. (See <a class="local">'Resistance to EGFR TKIs'</a> above.)</p><p class="headingAnchor" id="H21225246"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15811.html" rel="external">"Patient education: Non-small cell lung cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/890.html" rel="external">"Patient education: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for EGFR inhibitors</strong> – The presence of a characteristic mutation in the epidermal growth factor receptor (<em>EGFR</em>) defines a subset of patients with non-small cell lung cancer (NSCLC) who are likely to have a favorable response to EGFR tyrosine kinase inhibitors (TKIs). (See <a class="local">'Rationale'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment for driver mutations</strong> – Whenever possible, therapy of patients with advanced NSCLC should be individualized based upon the molecular and histologic features of the tumor. If feasible prior to treatment, patients should have tumor tissue assessed for the presence of a somatic mutation in the <em>EGFR</em> as well as for other driver mutations. (See <a class="local">'EGFR mutation as a predictor of responsiveness'</a> above and  <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy of single-agent EGFR tyrosine kinase inhibitors (TKIs)</strong> <strong>for common activating </strong><strong><em>EGFR</em></strong><strong> mutations</strong> – For patients with previously untreated metastatic NSCLC and an exon 19 deletion or exon 21 L858R activating mutation of the <em>EGFR</em>, we recommend monotherapy with an EGFR TKI rather than chemotherapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). In randomized trials, this approach significantly prolongs progression-free survival (PFS), although the impact on overall survival (OS) remains uncertain. (See <a class="local">'Efficacy of single-agent EGFR TKIs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with advanced <em>EGFR</em>-mutant NSCLC, we suggest <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> as the front-line treatment rather than other TKIs (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Data have shown PFS benefits with the addition of chemotherapy to osimertinib at the expense of added toxicity, but survival benefits are unknown. Although we have not incorporated this strategy into our clinical practice pending longer term data, we recognize that it is an acceptable strategy. (See <a class="local">'Alternatives'</a> above and <a class="local">'Preferred: Osimertinib, with or without chemotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of an EGFR inhibitor in combination with standard platinum-based chemotherapy regimens is not a standard option for patients with NSCLC that contains an <em>EGFR</em> mutation, given increased toxicity and the fact that trials were conducted prior to routine use of <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a>. Results with the combination of first-generation EGFR inhibitors and chemotherapy in the frontline setting are provocative, however, and deserving of further study. (See <a class="local">'Combination regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with previously untreated metastatic NSCLC but without an activating mutation of the <em>EGFR</em> should be treated with either chemotherapy or other targeted agents, depending upon the molecular characteristics of their tumor. (See <a class="local">'EGFR mutation as a predictor of responsiveness'</a> above and  <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with progression on EGFR inhibitors</strong> – For patients with an <em>EGFR</em> mutation who progress on a first- or second-generation EGFR TKI and are found to have a substitution of methionine for threonine at position 790 (<em>T790M</em>) mutation, we treat with <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a>. For those who do not have a <em>T790M</em> mutation, or for those who progress on osimertinib, subsequent management usually consists of cytotoxic chemotherapy and immunotherapy, in the same way as for other chemotherapy-naïve patients. The addition of the anti-programmed cell death ligand 1 (PD-L1) antibody <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> to <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and platinum-based doublet chemotherapy has been shown to improve outcomes in nonsquamous NSCLC, including among those with activating driver mutations, and is an off-label option in such patients upon progression on osimertinib. (See  <a class="medical medical_review" href="/z/d/html/4629.html" rel="external">"Subsequent line therapy in non-small cell lung cancer lacking a driver mutation"</a> and  <a class="medical medical_review" href="/z/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation", section on 'In nonsquamous cancers'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Continuing an EGFR TKI beyond progression and during subsequent treatment with chemotherapy is not recommended and is associated with shortened OS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uncommon </strong><strong><em>EGFR</em></strong><strong> mutations</strong> – For patients with <em>EGFR</em> exon 20 insertion-mutated NSCLC, we suggest the addition of <a class="drug drug_general" data-topicid="131693" href="/z/d/drug information/131693.html" rel="external">amivantamab</a> to front-line chemotherapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>), if available. If amivantamab is not available for front-line use, we use either amivantamab as a single agent after progression on platinum-based chemotherapy.</p><p></p><p class="bulletIndent1">For those with advanced NSCLC and <em>EGFR</em> S768I, L861Q, or G719X mutations, we suggest initial treatment with <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), although <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> is a reasonable alternative.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013; 137:828.</a></li><li><a class="nounderline abstract_t">Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014; 9:154.</a></li><li><a class="nounderline abstract_t">Moran T, Sequist LV. Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations. J Clin Oncol 2012; 30:3330.</a></li><li><a class="nounderline abstract_t">Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29:2866.</a></li><li class="breakAll">Osimertinib tablets. United States Prescribing Information. US National Library of Medicine. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf (Accessed on August 26, 2019).</li><li><a class="nounderline abstract_t">Kunimasa K, Oka T, Hara S, et al. Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction. Lung Cancer 2021; 153:186.</a></li><li><a class="nounderline abstract_t">Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378:113.</a></li><li><a class="nounderline abstract_t">Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med 2020; 382:41.</a></li><li><a class="nounderline abstract_t">Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med 2023; 389:1935.</a></li><li><a class="nounderline abstract_t">Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12:735.</a></li><li><a class="nounderline abstract_t">Zhou C, Wu YL, Chen G, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol 2015; 26:1877.</a></li><li><a class="nounderline abstract_t">Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13:239.</a></li><li><a class="nounderline abstract_t">Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 2015; 26:1883.</a></li><li><a class="nounderline abstract_t">Sharma M, Holmes HM, Mehta HB, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer 2019; 125:1155.</a></li><li class="breakAll">Drugs at FDA: FDA-Approved Drug Products. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Reports.MonthlyApprovalsAll (Accessed on August 26, 2019).</li><li><a class="nounderline abstract_t">Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947.</a></li><li><a class="nounderline abstract_t">Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11:121.</a></li><li><a class="nounderline abstract_t">Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013; 24:54.</a></li><li><a class="nounderline abstract_t">Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380.</a></li><li><a class="nounderline abstract_t">Oizumi S, Kobayashi K, Inoue A, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist 2012; 17:863.</a></li><li><a class="nounderline abstract_t">Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13:528.</a></li><li><a class="nounderline abstract_t">Wu YL, Zhou C, Hu CP, et al. LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol 2013; 31S: ASCO #8016.</a></li><li><a class="nounderline abstract_t">Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31:3327.</a></li><li><a class="nounderline abstract_t">Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31:3342.</a></li><li><a class="nounderline abstract_t">Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013; 31:3335.</a></li><li><a class="nounderline abstract_t">Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15:213.</a></li><li><a class="nounderline abstract_t">Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16:141.</a></li><li><a class="nounderline abstract_t">Park K, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016; 17:577.</a></li><li><a class="nounderline abstract_t">Paz-Ares L, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 2017; 28:270.</a></li><li><a class="nounderline abstract_t">Nishie K, Kawaguchi T, Tamiya A, et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol 2012; 7:1722.</a></li><li><a class="nounderline abstract_t">Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007; 13:5150.</a></li><li><a class="nounderline abstract_t">Oxnard GR, Miller VA. Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park) 2010; 24:392.</a></li><li><a class="nounderline abstract_t">Soria JC, Wu YL, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol 2015; 16:990.</a></li><li><a class="nounderline abstract_t">Mok TSK, Kim SW, Wu YL, et al. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol 2017; 35:4027.</a></li><li><a class="nounderline abstract_t">Passaro A, Leighl N, Blackhall F, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol 2022; 33:466.</a></li><li><a class="nounderline abstract_t">Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006; 12:5764.</a></li><li><a class="nounderline abstract_t">Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12:6494.</a></li><li><a class="nounderline abstract_t">Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352:786.</a></li><li><a class="nounderline abstract_t">Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73.</a></li><li><a class="nounderline abstract_t">Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104:20932.</a></li><li><a class="nounderline abstract_t">Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039.</a></li><li><a class="nounderline abstract_t">Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer 2009; 63:169.</a></li><li><a class="nounderline abstract_t">Piotrowska Z, Thress KS, Mooradian M, et al. MET amplification (amp) as a resistance mechanism to osimertinib. J Clin Oncol 2017; 35S: ASCO #9020.</a></li><li><a class="nounderline abstract_t">Jagadeeswaran R, Surawska H, Krishnaswamy S, et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res 2008; 68:132.</a></li><li><a class="nounderline abstract_t">Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009; 27:1667.</a></li><li><a class="nounderline abstract_t">Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3:75ra26.</a></li><li><a class="nounderline abstract_t">Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19:2240.</a></li><li><a class="nounderline abstract_t">Marcoux N, Gettinger SN, O'Kane G, et al. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol 2019; 37:278.</a></li><li><a class="nounderline abstract_t">Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372:1689.</a></li><li><a class="nounderline abstract_t">Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 2017; 376:629.</a></li><li><a class="nounderline abstract_t">Papadimitrakopoulou VA, Mok TS, Han JY, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol 2020; 31:1536.</a></li><li><a class="nounderline abstract_t">Mok T, Myung-Ju A, Han Ji-Youn, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3). J Clin Oncol 2017; 35S: ASCO #9005.</a></li><li><a class="nounderline abstract_t">Kim DW, Lee DH, Kang JH, et al. Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs). J Clin Oncol 2014; 32S: ASCO #8011.</a></li><li><a class="nounderline abstract_t">Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015; 372:1700.</a></li><li><a class="nounderline abstract_t">Sequist LV, Soria JC, Camidge DR. Update to Rociletinib Data with the RECIST Confirmed Response Rate. N Engl J Med 2016; 374:2296.</a></li><li><a class="nounderline abstract_t">Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 2018; 378:2288.</a></li><li><a class="nounderline abstract_t">Socinski MA, Jotte RM, Cappuzzo F, et al. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. J Clin Oncol 2018; 36S: ASCO #9002.</a></li><li><a class="nounderline abstract_t">Cappuzzo F, McCleod M, Hussein M, et al. Impower130: Progression-free survival (PFS) and safety analysis from a randomized phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Ann Oncol 2018; 29S: ESMO #LBA53.</a></li><li><a class="nounderline abstract_t">Oxnard GR, Hu Y, Mileham KF, et al. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 2018; 4:1527.</a></li><li><a class="nounderline abstract_t">Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med 2023; 389:2039.</a></li><li class="breakAll">Amivantamab-vmjw injection. United States Prescribing Information. US National Library of Medicine. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf (Accessed on May 26, 2021).</li><li><a class="nounderline abstract_t">Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol 2021; 39:3391.</a></li><li><a class="nounderline abstract_t">Piotrowska Z, Tan DS, Smit EF, et al. Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions. J Clin Oncol 2023; 41:4218.</a></li><li class="breakAll">Afatinib tablets. United States Prescribing Information. US National Library of Medicine. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf (Accessed on June 20, 2019).</li><li><a class="nounderline abstract_t">Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 2015; 16:830.</a></li><li><a class="nounderline abstract_t">Cho JH, Lim SH, An HJ, et al. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). J Clin Oncol 2020; 38:488.</a></li><li><a class="nounderline abstract_t">Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol 2019; 30:839.</a></li><li><a class="nounderline abstract_t">Lisberg A, Cummings A, Goldman JW, et al. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. J Thorac Oncol 2018; 13:1138.</a></li><li><a class="nounderline abstract_t">Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:4113.</a></li><li><a class="nounderline abstract_t">Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11:521.</a></li></ol></div><div id="topicVersionRevision">Topic 4630 Version 131.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23551194" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419411" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22753908" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670455" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670455" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33277055" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29151359" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31751012" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37937763" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21783417" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26141208" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22285168" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26105600" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30605231" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30605231" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19692680" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20022809" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22967997" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20573926" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22581822" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22452896" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23816960" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23816967" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23816963" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24439929" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25589191" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27083334" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28426106" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23059777" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785570" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20480735" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26159065" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28968167" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35176458" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17020982" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17085664" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728811" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15737014" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18093943" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17463250" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18672314" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : MET as a target for treatment of chest tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : MET amplification (amp) as a resistance mechanism to osimertinib</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172305" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19255323" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21430269" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23470965" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30550363" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25923549" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959700" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32861806" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25923550" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Rociletinib in EGFR-mutated non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27195670" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Update to Rociletinib Data with the RECIST Confirmed Response Rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29863955" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo)±bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Impower130: Progression-free survival (PFS) and safety analysis from a randomized phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30073261" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870976" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870976" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34339292" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37384848" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37384848" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26051236" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31825714" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30847464" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29874546" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21969500" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20493771" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
